In recent years, a number of preclinical models have shown that cannabinoids may be highly effective at improving inflammation and, therefore, may be a potential treatment for inflammatory bowel diseases.
A targeted program that allows all prescribers to access real-time data and track and compare their own performance with those of others can improve compliance with opioid prescribing guidelines.
The FDA has announced that it is requiring drug manufacturers for all opioid pain relievers and medicines to treat opioid use disorder to include new recommendations about naloxone to the prescribing information.
Over half of the sample attained opioids through their own prescription, and 47.2% of patients with co-occurring sedative use disorder attained sedatives by prescription.
An opinion piece highlights the growing concerns among medical professionals about the exacerbating effects the COVID-19 pandemic may have among people with opioid use disorder.
![Still routinely prescribed to manage chronic pain, opioids are oftentimes overused, misused, or abused by patients. These behaviors are associated with a number of adverse effects, the most serious of which, respiratory depression, can result in death. Affectively dysregulated patients may associate negative emotions with recurrent opioid use through operant learning. [9] It is therefore imperative to prevent, identify, and manage opioid misuse in those patients, and seek to adopt of multi-dimensional approach to the treatment of chronic pain. Numerous initiatives have been initiated, aiming to guide healthcare practitioners in face of the opioid epidemic.](https://1tvlpc3ybbcb2e1tavrfrmg1-wpengine.netdna-ssl.com/wp-content/uploads/sites/15/2019/01/drugsspilledoutts509483224_1104058.jpg)
